Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: Gene sequence variation and functional genomics

British Journal of Pharmacology

Volumn 161, Issue 7, 2010, Pages 1584-1598

  Wu, T Y ^a   Peng, Y ^b   Pelleymounter, L L ^a   Moon, I ^a   Eckloff, B W ^c   Wieben, E D ^c   Yee, V C ^b   Weinshilboum, Richard M ^a  

^a MAYO CLINIC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Functional genomics; IMPDH1; IMPDH2; Inosine monophosphate dehydrogenase; Mycophenolate mofetil; Mycophenolate sodium; Mycophenolic acid; Pharmacogenetics; Transplantation

Indexed keywords

INOSINATE DEHYDROGENASE; INOSINE MONOPHOSPHATE DEHYDROGENASE 1; INOSINE MONOPHOSPHATE DEHYDROGENASE 2; MESSENGER RNA; MYCOPHENOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; FUNCTIONAL GENOMICS; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

AFRICAN AMERICANS; ANIMALS; ASIAN AMERICANS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; ISOENZYMES; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; UNITED STATES;

EID: 78149405278     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00987.x     Document Type: Article

References (40)

1. Allison AC, Eugui EM (2000). Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47: 85-118.
2. Carr SF, Papp E, Wu JC, Natsumeda Y (1993). Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 268: 27286-27290.
3. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT (2005). Mapping determinants of human gene expression by regional and genome-wide association. Nature 437: 1365-1369.
4. Emsley P, Cowtan K (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
5. Fernandez A, Martins J, Villlafruela JJ, Marcen R, Pascual J, Cano T et al. (2007). Variability of mycophenolate mofetil trough levels in stable kidney transplant patients. Transplant Proc 39: 2185-2186.
6. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I et al. (2001). Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 34: 543-549.
7. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I et al. (2004). Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 4: 2045-2051.
8. Glander P, Sombogaard F, Budde K, Van Gelder T, Hambach P, Liefeldt L et al. (2009). Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit 31: 351-359.
9. Gu JJ, Spychala J, Mitchell BS (1997). Regulation of the human inosine monophosphate dehydrogenase type I gene. Utilization of alternative promoters. J Biol Chem 272: 4458-4466.
10. Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L et al. (2000). Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest 106: 599-606.
11. Gu JJ, Tolin AK, Jain J, Huang H, Santiago L, Mitchell BS (2003). Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice. Mol Cell Biol 23: 6702-6712.
12. Hartl DL, Clark AG (2007). Principles of Population Genetics, 4th edn. Sinauer Associates: Sunderland, MA.
13. Hedrick PW (2000). Genetics of Populations, 2nd edn. Jones and Bartlett Publishers: Sudbury, MA.
14. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV et al. (1998). Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367.
15. Ji Y, Gu J, Makhov AM, Griffith JD, Mitchell BS (2006). Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic acid by GTP. J Biol Chem 281: 206-212.
16. Ji Y, Moon I, Zlatkovic J, Salavaggione OE, Thomae BA, Eckloff BW et al. (2007). Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J Pharmacol Exp Ther 322: 529-540.
17. Kraulis PJ (1991). MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 19: 946-950.
18. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS (2009). Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford) 48: 944-952.
19. Merritt EA, Bacon DJ (1997). Raster3D: photorealistic molecular graphics. Methods Enzymol 277: 505-524.
20. Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA et al. (2008). Glutathione S-transferase P1: gene sequence variation and functional genomic studies. Cancer Res 68: 4791-4801.
21. Ogino S, Gulley ML, Den Dunnen JT, Wilson RB, Association E (2007). Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J Mol Diagn 9: 1-6.
22. Pisupati J, Jain A, Burckart G, Hamad I, Zuckerman S, Fung J et al. (2005). Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 45: 34-41.
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. (2007). PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
24. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002). Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70: 425-434.
25. Senda M, Natsumeda Y (1994). Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). Life Sci 54: 1917-1926.
26. Sombogaard F, Van Schaik RH, Mathot RA, Budde K, Van Der Werf M, Vulto AG et al. (2009). Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics 19: 626-634.
27. Spellicy CJ, Daiger SP, Sullivan LS, Zhu J, Liu Q, Pierce EA et al. (2007). Characterization of retinal inosine monophosphate dehydrogenase 1 in several mammalian species. Mol Vis 13: 1866-1872.
28. Tajima F (1989a). DNA polymorphism in a subdivided population: the expected number of segregating sites in the two-subpopulation model. Genetics 123: 229-240.
29. Tajima F (1989b). Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123: 585-595.
30. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG et al. (2004). Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res 10: 8301-8308.
31. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ (2005). GROMACS: fast, flexible, and free. J Comput Chem 26: 1701-1718.
32. Wang L, Sullivan W, Toft D, Weinshilboum R (2003). Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics 13: 555-564.
33. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM (2005). Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci USA 102: 9394-9299.
34. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R et al. (2007). A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 17: 283-290.
35. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R et al. (2008). IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 83: 711-717.
36. Weinshilboum R, Wang L (2004). Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther 75: 253-258.
37. Winnicki W, Weigel G, Sunder-Plassmann G, Bajari T, Winter B, Herkner H et al. (2010). An inosine 5'-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. Pharmacogenomics J 10: 70-76.
38. Wu JC (1994). Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Discov 2: 185-204.
39. Zimmermann AG, Spychala J, Mitchell BS (1995). Characterization of the human inosine-5'-monophosphate dehydrogenase type II gene. J Biol Chem 270: 6808-6814.
40. Zimmermann AG, Wright KL, Ting JP, Mitchell BS (1997). Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence. J Biol Chem 272: 22913-22923.